4.3 Review

Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes

期刊

JOURNAL OF DERMATOLOGICAL TREATMENT
卷 26, 期 4, 页码 329-334

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/09546634.2014.991673

关键词

Acitretin; ciclosporin; fumaric acid esters; methotrexate; pregnancy

资金

  1. Abbott/AbbVie
  2. Almirall-Hermal
  3. Amgen
  4. BASF
  5. Biogen Idec
  6. Celgene
  7. Centocor
  8. Eli Lilly
  9. Forward Pharma
  10. Galderma
  11. Janssen
  12. Leo Pharma
  13. Medac
  14. MSD
  15. Miltenyi Biotech
  16. Novartis
  17. Pfizer
  18. Teva
  19. VBL
  20. Xenoport
  21. Abbvie
  22. Actelion
  23. GSK-Stiefel
  24. Sandoz
  25. Trident
  26. UCB

向作者/读者索取更多资源

The effects of conventional systemic therapies for psoriasis on pregnancy outcomes, lactation, male fertility and mutagenicity are common concerns in the clinical setting. There is relatively little evidence to guide clinician and patient. In this study, we review the safety profile of the commonly used conventional systemic therapies used for psoriasis in individuals of reproductive potential. Safety data are derived from large-scale registries, adverse-event reporting databases, clinical trials and case reports. We assess the effect of each therapy on adverse pregnancy outcomes, including congenital malformations, and lactation with maternal administration. We also assess the effect of the therapies on male fertility and potential mutagenicity with paternal administration. We provide applicable guidance to inform clinician and patient before and after conception.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据